Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (4): 562-564. doi: 10.19723/j.issn.1671-167X.2024.04.002
Previous Articles Next Articles
树栋 张*(
),睿扬 谢
CLC Number:
- R737.1
| 1 |
Marshall FF , Dietrick DD , Baumgartner WA , et al. Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins[J]. J Urol, 1988, 139 (6): 1166- 1172.
doi: 10.1016/S0022-5347(17)42848-5 |
| 2 |
Reese AC , Whitson JM , Meng MV . Natural history of untreated renal cell carcinoma with venous tumor thrombus[J]. Urol Oncol, 2013, 31 (7): 1305- 1309.
doi: 10.1016/j.urolonc.2011.12.006 |
| 3 |
Tilki D , Nguyen HG , Dall-Era MA , et al. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus[J]. Eur Urol, 2014, 66 (3): 577- 583.
doi: 10.1016/j.eururo.2013.06.048 |
| 4 | 黄庆波, 彭程, 顾良友, 等. 肾肿瘤伴静脉瘤栓"301分级系统"及手术策略(附100例病例分析)[J]. 微创泌尿外科杂志, 2017, 6 (6): 328- 332. |
| 5 |
Aslam-Sohaib SA , Teh J , Nargund VH , et al. Assessment of tumor invasion of the vena caval wall in renal cell carcinoma cases by magnetic resonance imaging[J]. J Urol, 2002, 167 (3): 1271- 1275.
doi: 10.1016/S0022-5347(05)65280-9 |
| 6 | Zargar-Shoshtari K , Sharma P , Espiritu P , et al. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension[J]. Urol Oncol, 2015, 33 (3): 112. |
| 7 | Tabbara MM, Gonzalez J, Ciancio G. Renal cell carcinoma with supradiaphragmatic tumor thrombus: Avoiding sternotomy and cardiopulmonary bypass[J]. Med Res Arch, 2022(2022-07-31)[20230-1-15]. https://pubmed.ncbi.nlm.nih.gov/36714035. |
| 8 |
Thiel DD , Lohse CM , Arnold ML , et al. Does left side renal cell carcinoma (RCC) with renal vein/vena cava thrombus predict worse prognosis than equivalent right side RCC tumor thrombus?[J]. Int Urol Nephrol, 2012, 44 (4): 1005- 1012.
doi: 10.1007/s11255-012-0168-2 |
| 9 |
Zhang Y , Bi H , Fu Y , et al. Cephalic inferior vena cava non-clamping technique versus standard procedure for robot-assisted laparoscopic level Ⅱ-Ⅲ thrombectomy: A prospective cohort study[J]. Int J Surg, 2023, 109 (6): 1594- 1602.
doi: 10.1097/JS9.0000000000000209 |
| 10 |
Cost NG , Delacroix SE , Jr. , Sleeper JP , et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus[J]. Eur Urol, 2011, 59 (6): 912- 918.
doi: 10.1016/j.eururo.2011.02.032 |
| 11 |
Bigot P , Fardoun T , Bernhard JC , et al. Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: Is it useful?[J]. World J Urol, 2014, 32 (1): 109- 114.
doi: 10.1007/s00345-013-1088-1 |
| 12 |
Zhang Y , Li Y , Deng J , et al. Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma[J]. PLoS One, 2015, 10 (2): e0115896.
doi: 10.1371/journal.pone.0115896 |
| 13 |
Field CA , Cotta BH , Jimenez J , et al. Neoadjuvant sunitinib decreases inferior vena caval thrombus size and is associated with improved oncologic outcomes: A multicenter comparative analysis[J]. Clin Genitourin Cancer, 2019, 17 (3): e505- e512.
doi: 10.1016/j.clgc.2019.01.013 |
| 14 |
Stewart GD , Welsh SJ , Ursprung S , et al. A Phase Ⅱ study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)[J]. Br J Cancer, 2022, 127 (6): 1051- 1060.
doi: 10.1038/s41416-022-01883-7 |
| 15 |
Zhang Z , Xiong L , Wu Z , et al. Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma[J]. Transl Androl Urol, 2021, 10 (5): 2091- 2102.
doi: 10.21037/tau-21-406 |
| 16 |
Labbate C , Hatogai K , Werntz R , et al. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy[J]. J Immunother Cancer, 2019, 7 (1): 66.
doi: 10.1186/s40425-019-0546-8 |
| 17 |
Hara T , Terakawa T , Hyodo T , et al. Pathological complete response of renal cell carcinoma with vena cava tumor thrombus to neoadjuvant TKI/IO combination therapy[J]. Urol Case Rep, 2021, 39, 101800.
doi: 10.1016/j.eucr.2021.101800 |
| 18 |
Powles T , Tomczak P , Park SH , et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23 (9): 1133- 1144.
doi: 10.1016/S1470-2045(22)00487-9 |
| 19 |
Choueiri TK , Tomczak P , Park SH , et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma[J]. N Engl J Med, 2021, 385 (8): 683- 694.
doi: 10.1056/NEJMoa2106391 |
| 20 |
Wu Z , Chen H , Chen Q , et al. Prognostic significance of grade discrepancy between primary tumor and venous thrombus in nonmetastatic clear-cell renal cell carcinoma: Analysis of the REMEMBER registry and implications for adjuvant therapy[J]. Eur Urol Oncol, 2024, 7 (1): 112- 121.
doi: 10.1016/j.euo.2023.06.006 |
| [1] | Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679. |
| [2] | Binshuai WANG,Min QIU,Qianjin ZHANG,Maofeng TIAN,Lei LIU,Guoliang WANG,Min LU,Xiaojun TIAN,Shudong ZHANG. Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 636-639. |
| [3] | Jie YANG,Jieli FENG,Shudong ZHANG,Lulin MA,Qing ZHENG. Clinical effects of transesophageal echocardiography in different surgical methods for nephrectomy combined with Mayo Ⅲ-Ⅳ vena tumor thrombectomy [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 631-635. |
| [4] | Kewei CHEN,Zhuo LIU,Shaohui DENG,Fan ZHANG,Jianfei YE,Guoliang WANG,Shudong ZHANG. Clinical diagnosis and treatment of renal angiomyolipoma with inferior vena cava tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 617-623. |
| [5] | Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588. |
| [6] | Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666. |
| [7] | Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672. |
| [8] | Kewei CHEN,Shaohui DENG,Zhuo LIU,Hongxian ZHANG,Lulin MA,Shudong ZHANG. Discussion on the surgical timing of rupture and hemorrhage of renal angiomyolipoma [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 326-331. |
| [9] | Yun-chong LIU,Zong-long WU,Li-yuan GE,Tan DU,Ya-qian WU,Yi-meng SONG,Cheng LIU,Lu-lin MA. Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 781-792. |
| [10] | Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801. |
| [11] | Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811. |
| [12] | Dong LAN,Zhuo LIU,Yu-xuan LI,Guo-liang WANG,Xiao-jun TIAN,Lu-lin MA,Shu-dong ZHANG,Hong-xian ZHANG. Risk factors for massive hemorrhage after radical nephrectomy and removal of venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 825-832. |
| [13] | Min QIU,You-long ZONG,Bin-shuai WANG,Bin YANG,Chu-xiao XU,Zheng-hui SUN,Min LU,Lei ZHAO,Jian LU,Cheng LIU,Xiao-jun TIAN,Lu-lin MA. Treatment outcome of laparoscopic partial nephrectomy in patients with renal tumors of moderate to high complexity [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 833-837. |
| [14] | 聪 田,军 刘,波 杨,佳佳 乔,晓波 黄,清泉 许. [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 948-952. |
| [15] | Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282. |
|
||